 |
|
Chronic, Recurrent Small-Vessel Cutaneous VasculitisClinical Experience in 13 Patients
Thomas R. Cupps, MD;
Robert M. Springer, MD;
Anthony S. Fauci, MD
JAMA. 1982;247(14):1994-1998.
Abstract
The clinical experience in 13 patients with small-vessel cutaneous vasculitis limited to the skin is presented. Within the spectrum of what is referred to as "hypersensitivity vasculitis," this group of patients represents a distinctive clinical entity characterized by (1) clinical, laboratory, and histopathologic features of the hypersensitivity vasculitis group; (2) chronic and recurrent isolated cutaneous vasculitic eruptions; (3) absence of disease progression to systemic involvement during long-term follow-up; and (4) relative unresponsiveness to immunosuppressive therapy, including treatment with corticosteroids (prednisone) and cyclophosphamide. Because this disease remains limited to the skin, potentially toxic immunosuppressive regimens with prolonged daily corticosteroids or cytotoxic agents should be avoided. Treatment of local symptoms, particularly lower extremity pain, remains a difficult treatment problem in some patients.
(JAMA 1982;247:1994-1998)
Author Affiliations
From the Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Md.
Footnotes
Reprint requests to Laboratory of Immunoregulation, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bldg 10, Room 11B-13, Bethesda, MD 20205 (Dr Cupps).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Prognostic Factors in Leukocytoclastic Vasculitis: A Clinicopathologic Study of 160 Patients
Sais et al.
Arch Dermatol 1998;134:309-315.
ABSTRACT
| FULL TEXT
Colchicine in the Treatment of Cutaneous Leukocytoclastic Vasculitis: Results of a Prospective, Randomized Controlled Trial
Sais et al.
Arch Dermatol 1995;131:1399-1402.
ABSTRACT
|
